Journal: Journal of Clinical Pharmacology

Article Title: Prediction of Moxifloxacin Concentrations in Tuberculosis Patient Populations by Physiologically Based Pharmacokinetic Modeling

doi: 10.1002/jcph.1972

Figure Lengend Snippet: Pharmacokinetic curves of moxifloxacin with and without rifampicin coadministration of in‐house collected therapeutic drug monitoring (TDM) data for 400 mg of moxifloxacin only (A), 400 mg moxifloxacin with any dose of rifampicin (B), and 600 mg of moxifloxacin with any dose of rifampicin (C); median rifampicin dose for both group B and C was 1200 mg once daily (range, 450‐2000 mg). The x‐axis indicates time after last dose. Open circles and crosses indicate measured individual data from in‐house TDM data of patients with Mycobacterium tuberculosis or nontuberculous mycobacteria infections, respectively; the solid black lines indicate the fitted plasma concentration‐time curve using locally estimated scatterplot smoothing regression; and the gray area represents the 95% confidence interval around the regression. AUC 0‐24 , area under the plasma concentration–time curve from time 0 to 24 hours; C max , maximum plasma concentration.

Article Snippet: Individual plasma concentrations were plotted against time and a plasma concentration‐time curve was fitted using locally estimated scatterplot smoothing regression in R Studio version 1.1.463 (RStudio, Inc, Boston, Massachusetts) after which a C max was determined.

Techniques: Clinical Proteomics, Concentration Assay

Journal: Environmental research

Article Title: Differences in urine cadmium associations with kidney outcomes based on serum creatinine and cystatin C

doi: 10.1016/j.envres.2011.07.012

Figure Lengend Snippet: Scatterplot between MDRD eGFR and multi-variable cystatin C eGFR in 712 Korean lead workers. The line of equivalency (solid) and a smoothed line (dotted), which was estimated using the scatterplot smoothing method (SAS/GRAPH software), are shown.

Article Snippet: The line of equivalency (solid) and a smoothed line (dotted), which was estimated using the scatterplot smoothing method (SAS/GRAPH software), are shown. table ft1 table-wrap mode="anchored" t5 caption a7 Urine creatinine Urine cadmium μg/g Serum cystatin C Serum creatinine Single variable cystatin C eGFR Multi-variable cystatin C eGFR Dual eGFR MDRD eGFR Unadjusted urine cadmium μg/L 0.69 c 0.51 c 0.13 c −0.12 c −0.13 c −0.18 c −0.06 0.03 Urine creatinine, mg/dL −0.22 c 0.08 a 0.13 c −0.08 a 0.004 0.02 0.03 Urine cadmium μg/g 0.07 −0.34 c −0.07 −0.24 c −0.10 b 0.01 Serum cystatin C, mg/L 0.37 c −1.0 c −0.93 c −0.76 c −0.47 c Serum creatinine, mg/dL −0.37 c −0.19 c −0.59 c −0.73 c Single variable cystatin C eGFR, mL/min/1.73 m 2 0.93 c 0.76 c 0.47 c Multi-variable cystatin C eGFR, mL/min/1.73 m 2 0.80 c 0.50 c Dual biomarker eGFR, mL/min/1.73 m 2 0.90 c Open in a separate window a p-value less than 0.05; b p-value less than 0.01; c p-value less than 0.001 Spearman correlation coefficients for urine cadmium, urine creatinine and kidney function measures in 712 lead workers

Techniques: Software